Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Clenoliximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Clenoliximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Clenoliximab. |
| Estrone | Estrone may increase the thrombogenic activities of Clenoliximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Clenoliximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Clenoliximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Clenoliximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Clenoliximab. |
| Estriol | Estriol may increase the thrombogenic activities of Clenoliximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Clenoliximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Clenoliximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Clenoliximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Clenoliximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Clenoliximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Clenoliximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Clenoliximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Clenoliximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Clenoliximab. |
| Equol | Equol may increase the thrombogenic activities of Clenoliximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Clenoliximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Clenoliximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Clenoliximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Clenoliximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Clenoliximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Clenoliximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Clenoliximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Clenoliximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Clenoliximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Clenoliximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Clenoliximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Clenoliximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Clenoliximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Clenoliximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Clenoliximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Clenoliximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clenoliximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Clenoliximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Clenoliximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Clenoliximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Clenoliximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Clenoliximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Clenoliximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Clenoliximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clenoliximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Clenoliximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clenoliximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Clenoliximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Clenoliximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clenoliximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Clenoliximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Clenoliximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Clenoliximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clenoliximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Clenoliximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Clenoliximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Clenoliximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Clenoliximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Clenoliximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Clenoliximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Clenoliximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Clenoliximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Clenoliximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Clenoliximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Clenoliximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Clenoliximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Clenoliximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Clenoliximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Clenoliximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Clenoliximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Clenoliximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Clenoliximab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Clenoliximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Clenoliximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Clenoliximab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Clenoliximab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Clenoliximab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Clenoliximab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Clenoliximab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Clenoliximab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Clenoliximab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Clenoliximab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Clenoliximab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Clenoliximab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Clenoliximab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Clenoliximab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Clenoliximab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Clenoliximab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Clenoliximab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Clenoliximab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Clenoliximab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Clenoliximab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Clenoliximab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Clenoliximab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Clenoliximab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Clenoliximab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Clenoliximab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Clenoliximab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Clenoliximab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Clenoliximab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Clenoliximab. |